Alan and his team are responsible for discovering new immuno-oncology targets and moving them from discovery through pre-clinical development.
Alan joined Medarex in 2000 (which was acquired by BMS in 2009). During his tenure at Medarex/BMS he and his team have spent their time studying the role of CTLA-4, PD-1 and PD-L1 and their roles in treating cancer. Under his supervision, Alan and his team have been responsible for the preclinical development for the first approved checkpoint inhibitor. More recently, Alan and his team have conducted preclinical research evaluating the combination of PD-1 and CTLA-4 in multiple tumor types. Today, Alan’s team continues to conduct research of potential new immuno-oncology targets including anti-LAG-3 and anti-GITR.
Alan received his Ph.D. from Harvard University in 1984 and was a Whitehead Fellow at the Whitehead Institute, Massachusetts Institute of Technology from 1984 to 1989. He was also a Chargé de Recherche at the Institut Pasteur from 1990 to 1993. He has worked in the biotechnology and pharmaceutical industry since 1993.